Halifax, NS – MedMira, a developer and marketer of rapid diagnostic technology and solutions, says that the Centers for Disease Control and Prevention (CDC) in the United States has selected the company’s Multiplo HIV/Hepatitis C (HCV) Rapid Test to be a part of a program entitled “Opportunity to Collaborate in the Evaluation of Rapid Diagnostic Tests for HIV and HCV”.
This program of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) at the CDC of the department of health and human services (DHHS) will see evaluations done in laboratories and in the field to determine the viability of rapid tests for use in screening and/or diagnosis of HIV and HCV in the US. A number of rapid tests will be evaluated as part of the program, however, the company says Multiplo HIV/HCV will be the only combination rapid flow-through test with the ability to deliver simultaneous results for HIV and HCV.
“We are very pleased that our Multiplo HIV/HCV test was selected for evaluation in this important CDC program. International evaluations and feedback from leading researchers have been very positive and we fully expect that our proven technology platform will continue to exceed expectations as part of this program,” said Hermes Chan, CEO of MedMira. “In today’s economy, where every healthcare budget is being closely scrutinized, a multiple test makes the most sense. Multiplo is essentially a 2-in-1 test that costs the healthcare provider less while delivering results faster than any two single tests combined. It is a win-win for healthcare providers and their patients.”